


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sbpgroup.com](http://www.sbpgroup.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**  
**APPOINTMENT OF CHIEF MEDICAL OFFICER AND**  
**HEADS OF CLINICAL DEVELOPMENT**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Dr. Kang Xiaoyan has been appointed as the Chief Medical Officer by the Company, Dr. Liu Meng has been appointed as Head of Clinical Development for Chronic Diseases by the Company, and Dr. Liu Rongjun has been appointed as Head of Clinical Development for Autoimmune Diseases by the Company.

Dr. Kang Xiaoyan has formally assumed the role of the Group’s Chief Medical Officer, taking overall responsibility for coordinating the global clinical development and clinical collaborations of innovative drugs across all therapeutic areas.

Dr. Kang Xiaoyan has over twenty five years of experience in clinical practice and drug research and development (“**R&D**”), possessing extensive expertise in clinical operations and strategic leadership, with a diverse background spanning multinational pharmaceutical companies and leading domestic innovative pharma companies. Dr. Kang completed her postdoctoral research in immunology at Cornell University Medical College in the United States. She has previously held key positions such as the Executive Deputy General Manager of the Clinical R&D Centre and the Chief Medical Officer for Oncology at companies including Bayer, Boehringer Ingelheim, Hengrui Pharmaceuticals, Junshi Biosciences and Qilu Pharmaceutical. She previously led the global clinical development and overall medical strategy for innovative oncology drugs, bispecific antibodies and small-molecule targeted drugs. She efficiently advanced several cutting-edge innovative candidates with First-in-Class and Best-in-Class potential into global multi-centre clinical studies, whilst at the same time published numerous high-impact academic papers.

Dr. Liu Meng has officially assumed the role of the Group's Head of Clinical Development for Chronic Diseases, taking overall responsibility for the clinical development of innovative drugs and medical strategies in the area.

Dr. Liu Meng holds a PhD and MD in Endocrinology from Fudan University and possesses many years of clinical experience, as well as working experience for nearly twenty years at leading multinational pharmaceutical companies and top domestic innovative pharma companies, covering major therapeutic areas such as metabolism, cardiovascular, respiratory diseases and oncology. Dr. Liu Meng has previously held key positions such as Head of Medical Affairs for Therapeutic Areas and Director of Medical Science at companies including GSK, Boehringer Ingelheim and Innovent Biologics. Prior to joining the Group, she served as the Head of Medicines and Clinical Development at Hasten Biopharmaceutical. Dr. Liu Meng has long led clinical strategies, regulatory filings, and clinical operations of innovative drugs both domestically and internationally. She previously led the development and implementation of clinical development strategies for several innovative drugs, including IBI362 (mazdutide), from Phase I to the New Drug Application (NDA) phase, and a number of her research findings have been published in top-tier journals and presented at prestigious international academic conferences. Furthermore, she has extensive experience in global multi-centre clinical trials, post-marketing real-world studies, and high-level academic collaborations, demonstrating both a global vision and solid industry experience.

Dr. Liu Rongjun has officially assumed the role of the Group's Head of Clinical Development for Autoimmune Diseases, taking overall responsibility for clinical development of innovative drugs and medical strategies in the area.

Dr. Liu Rongjun holds a PhD in Immunology from Fudan University and has both clinical experience at a top-tier hospital and over fifteen years' experience of R&D leadership in innovative drug development. He has long focused on autoimmune and chronic diseases, including rheumatology, dermatology and nephrology. Dr. Liu Rongjun has previously held positions at leading biopharmaceutical companies including Hutchison Whampoa, Reistone Biopharma and Lynk Pharmaceuticals; prior to joining the Group, Dr. Liu Rongjun served as the Vice President of Medical Affairs at Createrna Science and Technology, where he was fully responsible for pipeline development and clinical development strategies across the fields of immunology, nephrology, hematology and gastroenterology. Dr. Liu Rongjun possesses extensive experience in global clinical development and regulatory filings in both China and the US. He has led the clinical development and registration of several blockbuster innovative drugs; spearheaded the clinical development of ivarmacitinib, the first domestically developed JAK inhibitor, and successfully advanced multiple indications to market approval; and supported numerous innovative drugs in obtaining Breakthrough Therapy and Priority Review designations. He possesses end-to-end hands-on experience from clinical development to regulatory approval.

The Group has established a clear and robust clinical R&D structure across four major therapeutic areas: oncology, liver/cardiometabolic diseases, respiratory/autoimmune diseases, and surgery/analgesia. With the joining of these industry-leading talents and drawing on their outstanding clinical R&D capabilities and extensive management experience, the Group will be fully empowered in innovation, R&D, and global collaboration, thereby effectively driving the implementation of the Group's innovation and globalisation strategies.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 28 April 2026

*As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*